Sacituzumab govitecan
Sacituzumab govitecan (previously IMMU-132) is an antibody-drug conjugate being investigated as a treatment for cancers such as pancreatic cancers, small-cell lung cancer (SCLC) and triple-negative breast cancer.[1]
It is a conjugate of the humanized anti-Trop-2 monoclonal antibody (hRS7) with SN-38, the active metabolite of irinotecan.[2]
Clinical
A poster presentation reported some activity in a phase II trial for metastatic gastrointestinal cancers.[3] Activity has been seen in a phase II trial for metastatic triple-negative breast cancer (TNBC);[4] these results led to designation by the FDA as Breakthrough Therapy, an expedited investigational drug development pathway, in February 2016.[5]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />External links
- IMMU-132 (Sacituzumab Govitecan) Mentions FDA Orphan drug status, mechanism of action, and clinical trials
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- ↑ FDA Fast Track for TNBC
- ↑ Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. 2015
- ↑ P-162 Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers
- ↑ Immunomedics Reports Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment
- ↑ New Therapy Shows Early Promise, Continues to Progress in Triple-Negative Breast Cancer. Feb 2016
